Amgen Inc. (AMGN)

269,12 -2,19 (-0,81 %) À la clôture : 04:00PM EST

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 25 200

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Robert A. Bradway	Chairman, CEO & President	5,49M	S.O.	1963
Mr. Peter H. Griffith	Executive VP & CFO	2,57M	S.O.	1959
Mr. Esteban Santos	Executive Vice President of Operations	2,52M	S.O.	1968
Dr. David M. Reese M.D.	Executive Vice President of Research & Development	2,83M	S.O.	1963
Mr. Murdo Gordon	Executive VP of Global Commercial Operations	2,72M	S.O.	1967
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Finance	S.O.	S.O.	1974
Mr. Mike Zahigian	Senior VP & Chief Information Officer	S.O.	S.O.	S.O.
Mr. Arvind Sood	Vice President of Investor Relations	S.O.	S.O.	S.O.
Mr. Jonathan P. Graham	Executive VP, General Counsel & Secretary	2,44M	S.O.	1961
Ms. Nancy A. Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	S.O.	S.O.	1968

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Amgen Inc. en date du 1 décembre 2023 est 2. Les scores principaux sont Audit : 2; Société : 8; Droits des actionnaires : 1; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.